WIRobotics is betting that years of real-world movement data could shape the next generation of humanoid robots
Updated
May 19, 2026 5:10 PM

3D render of a person in various colours. PHOTO: UNSPLASH
Investor interest in humanoid robotics is continuing to grow as startups race to build systems capable of working alongside humans in real-world environments. That momentum was reflected after WIRobotics announced a KRW 95 billion (USD 68 million) Series B funding round to accelerate development of its humanoid robotics platform, ALLEX.
The Seoul-based startup said the funding comes roughly two years after its KRW 13 billion Series A round in 2024. JB Investment led the financing alongside investors including InterVest, Hana Ventures, Smilegate Investment, SBVA, NH Investment & Securities, Company K Partners, GU Investment and FuturePlay.
WIRobotics has spent the past several years building wearable robotics systems designed to assist human movement. The startup is now using that foundation to expand deeper into humanoid robotics and Physical AI, a category focused on AI systems that can interact with the physical world through movement, perception and manipulation.
Its humanoid platform, ALLEX, is being developed to support human-level object manipulation and interaction capabilities. The startup was recently selected for NVIDIA’s Physical AI Fellowship, a global robotics and AI development initiative aimed at supporting next-generation robotics research.
Rather than building humanoid systems entirely from scratch, WIRobotics is drawing on movement data collected through its wearable walking-assist robot, WIM. Over the past three years, the startup says it has built large real-world datasets around gait patterns, mobility and human movement control.
That wearable robotics business has also started showing commercial traction. WIM has sold more than 3,000 cumulative units and expanded into overseas markets including Europe, China, Türkiye and Japan. Revenue grew from KRW 560 million in 2023 to KRW 1.3 billion in 2024, then to KRW 2.79 billion in 2025. According to the startup, first-quarter 2026 revenue has already surpassed its full-year 2024 total.
The startup believes that real-world movement data collected through wearable robotics could become a competitive advantage as humanoid systems move closer to commercial deployment. WIRobotics is also expanding its global footprint alongside its robotics development efforts. The startup said it is establishing a North American entity in California while growing partnerships with overseas distributors and healthcare networks.
Its humanoid ambitions are moving into a more operational phase as well. Beginning later this year, WIRobotics plans to supply a research-focused version of its Mobile ALLEX platform to global research institutions and international partners for testing and collaborative development. The startup is also in discussions with a global automotive manufacturer around manufacturing-focused platform validation projects.
Yeonbaek Lee said: "This investment represents global recognition that the real-world movement data and control technologies accumulated through wearable robotics can evolve into next-generation humanoid robotics. We aim to accelerate the arrival of humanoid robots capable of interacting naturally with people".
Yongjae Kim added: "All investors from our previous Series A round participated again in this Series B financing, demonstrating strong confidence in WIRobotics' technological capabilities and growth potential amid intensifying global humanoid competition. Our mission is to realize humanoids capable of fundamentally human-like interaction and force control, driving a paradigm shift in high-performance manipulation technologies".
As competition intensifies across humanoid robotics, startups are increasingly trying to differentiate themselves through real-world deployment data rather than simulation alone. WIRobotics is positioning its wearable robotics business as the foundation for that transition, betting that years of human movement data could help shape the next generation of humanoid systems.
Keep Reading
From AI diagnostics to exoskeletons, the event highlights how healthcare tech is moving into real-world use
Updated
May 1, 2026 2:25 PM

Tesla Bot Optimus, designed by Tesla. PHOTO: ADOBE STOCK
The China International Medical Equipment Fair 2026 will open in Shanghai from April 9 to 12 at the National Exhibition and Convention Center. It is one of the largest gatherings in the medical device industry. This year’s edition will cover more than 320,000 square metres. Nearly 5,000 companies and brands are expected to participate, representing over 20 countries and regions. Organisers also expect more than 200,000 professional visitors and buyers from around 150 markets.
A key focus this year is the growing use of artificial intelligence in healthcare. One of the headline technologies is an AI agent designed to carry out multiple diagnoses from a single scan. The exhibition will also feature diagnostic software that is already in clinical use. In addition, an integrated platform for AI training and inference will be showcased to improve computing capacity within healthcare institutions.
Robotics will also play a central role at the event. New systems across surgical procedures, rehabilitation and elderly care are expected to be presented. Together, these developments point to a steady move toward more precise and assisted forms of care. Many of these technologies are designed to support clinicians and patients, especially in tasks that require consistent accuracy or long-term physical assistance.
For the first time, the event will introduce a dedicated Future Tech Arena. It will focus on brain-computer interfaces, embodied intelligence and university-led innovation. The space will include AI-assisted MRI systems for Alzheimer’s diagnosis. It will also feature brain-computer interface technologies used for cognitive assessment and training, along with wearable robotic exoskeletons.
Alongside product showcases, the event will continue to act as a platform for international trade and collaboration. An International Zone will host exhibitors from countries such as the United States, Germany, Japan, South Korea, the United Kingdom, France, Singapore, Malaysia and Thailand. This provides a view of how different markets are approaching medical technology. It also reflects the global nature of innovation and deployment in this sector.
The programme will include a set of networking and exchange formats under its “We” initiative. These include discussion stages with representatives from consulates and industry organisations, as well as matchmaking sessions based on verified buyer demand. Guided tours will also be organised to help international visitors connect with relevant exhibitors. In parallel, organisers are working with hospital partners to provide medical support services for attendees during the event.
Across the four days, hundreds of forums are scheduled. These will bring together policymakers, researchers and industry leaders to discuss regulatory frameworks, market access and the future of healthcare innovation. Some of these sessions will be led by the Global Harmonization Working Party in collaboration with the Ministry of Health of Malaysia, with a focus on regulatory alignment and cross-border cooperation in medical devices.
As healthcare systems continue to adopt digital tools and advanced equipment, events like CMEF provide a clear view of how these technologies are being developed and applied. The scale of participation this year reflects continued activity across both innovation and international collaboration in the medical device sector.